Anti-influenza therapeutic solutions, whether preventive or curative, are sub-optimal. Antivirals currently on the market have a very short efficacy window, which calls into question their real-life effectiveness.
The innovative SAChA project provides proven curative efficacy several days after the initial influenza infection. This natural metabolite of interest simultaneously targets viral multiplication and the excessive inflammatory response. It is this dual effect that confers a crucial advantage in the treatment of serious complications of influenza, surpassing the capabilities of current treatments.
Watch the video presentation of the SAChA project here :